TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations

NCT ID: NCT05407012

Last Updated: 2024-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-05

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project aims to study the immune responses to peanut allergen in those with a skin barrier defect with and without skin massage, specifically it aims to:

1. Establish if peanut allergen components can pass into human skin through regular massage using the peanut protein-containing extract.
2. Clarify whether this effect is amplified in those with an impaired skin barrier (AD and dry skin vs healthy controls).
3. Assess whether peanut protein components can be detected in interstitial skin fluid (ISF) using a suction device.
4. Test whether peanut protein components present in ISF are able to induce activation of basophils in blood of peanut allergic donors.
5. Assess whether the transcutaneous uptake of peanut protein can be reduced by the prior use of a barrier enhancing cream.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims to understand how peanut processing methods and peanut co-administration with oils, as is standard during the industrial processing of peanuts, influences the development of peanut allergy through the skin.

Cutaneous exposure of allergens is a crucial, but hitherto under explored route of food sensitisation, that if understood could lead to the development of translatable strategies to prevent food allergy. Food processors require a greater understanding of how allergen exposure cause allergy so that they can adapt their processing methods to counteract these exposure processes. Furthermore, this proposed research aligns with on-going efforts across Europe to address the increasing problems associated with food allergy but it is unique in that it focuses on cutaneous allergen exposure, which is a field in desperate need of more systematic study.

The assembled team of investigators (from the UK, Germany and France) joined by a peanut industry partner (Levantine) and patient and consumer representatives will aim to address the following hypotheses:

Understanding the mechanisms by which:

* Peanut proteins pass into the skin via the appendages to trigger an immune response.
* Skin stretching that occurs during massage opens up the skin appendages allowing more peanut protein into the skin and leads to dendritic cell activation and induction of T helper 2 cell response.
* Co-administration of peanut proteins and an oil to the skin increases allergenicity.
* Skin barrier impairment and inflammation (AD) increases allergenicity.

Test novel approaches to peanut allergy prevention whereby:

* Modifications in peanut processing can reduce allergen exposure via the skin.
* Meticulous hand hygiene reduces skin contamination with peanut protein.
* Application of a barrier enhancing cream can strengthen the skin barrier, in particular in those with atopic dermatitis, and reduce the risk of transcutaneous sensitisation further.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergy;Food Food Allergy Peanut Pathways and Sources of Exposure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention of the barrier enhancing preparation

Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.

Group Type EXPERIMENTAL

Application of the barrier enhancing preparation.

Intervention Type OTHER

Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;

Absence of the barrier enhancing preparation

Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Application of the barrier enhancing preparation.

Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult healthy volunteers (50% of the cohort), and adults with dry skin and AD (fulfilling the refined Hanifin and Rajka criteria, 50% of the cohort).
* Willingness to apply the study intervention and to not use any other topical preparations over theforearms during the study period.

Exclusion Criteria

* History of peanut allergy.
* Positive skin prick test to peanut (\>0 mm).
* No regular consumption of peanut products.
* Widespread AD, in particular if this involves the test sites of the forearms.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Bonn

OTHER

Sponsor Role collaborator

Institut Curie

OTHER

Sponsor Role collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role collaborator

Levantine UK

UNKNOWN

Sponsor Role collaborator

King's College London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carsten Flohr

Role: PRINCIPAL_INVESTIGATOR

King's College London

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Unit for Population-Based Dermatology Research

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stuart Jones

Role: CONTACT

0207 848 4506

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Preeti Kaur Khurana, MSc

Role: primary

+44 (0) 20 7188 7188 ext. 57716

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RE19787

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Food Oral Immunotherapy for Peanut Allergy
NCT04222491 ENROLLING_BY_INVITATION PHASE2
Persistence of Oral Tolerance to Peanut
NCT01366846 COMPLETED PHASE2
Improved Diagnostics in Food Allergy Study
NCT06097572 ENROLLING_BY_INVITATION NA
Tolerance Following Peanut Oral Immunotherapy
NCT01750879 COMPLETED PHASE1/PHASE2